Second Sight Medical Products Inc (NASDAQ: EYES) is having an overwhelmingly strong day in the market today, and for good reason. The company issued a press release early this morning announcing that it has seen record implants of its key product as well as the first human implant of another. Today, we’ll talk about the news, what we’re seeing from EYES, and what we’ll be watching for ahead.
EYES Gains On Implant News
As mentioned above, Second Sight Medical Products is having a strong start to the trading session this morning after announcing an update with regard to several key performance metrics. Here’s what we saw from the update:
- Argus II Retinal Prosthesis System – During the fourth quarter, 30 Argus II Retinal Prosthesis Systems were implanted, bringing the total number in 2017 to 75. This shows strong year-over-year growth in the amount of 329% on a quarterly level and 79% on an annual level.
- Orion Cortical Visual Prosthesis System – Also, EYES announced the first human implant of the Orion Cortical Visual Prosthesis System. The implant was performed by Nader Pouratian, MD, Ph.D., Vice Chairman of the Department of Neurosurgery at the Ronald Reagan UCLA Medical Center. This was completed in late January as part of the company’s feasibility clinical study.
In a statement, Will McGuire, President and CEO at EYES, had the following to offer:
We are excited about our milestones and achievements in 2017, which speak to the strength of our business and the momentum we expect for continued success in 2018.
We continue to advance our Argus II R&D efforts and have initiated screening for a clinical trial in better-sighted RP patients. Second Sight is committed to executing on our strategy to expand the availability of the Argus II to a larger patient population and explore the potential of our technology to treat those suffering from other forms of blindness. We look forward to updating investors on our continued progress.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!